



1 2 3 4 5 6



**FIG. 1**

1 2 3 4 5




***FIG. 2***

1 2 3 4 5 6




***FIG. 3***



***FIG. 4***




FDCPmix proliferation inhibition by  
INPROL: direct effect *in vitro*



**FIG. 6**


INPROL effects dynamic of CFU's proliferation inhibition



**FIG. 7**


**FIG. 8**

INPROL injected *in vivo* protects mice  
from the lethal duple 5FU treatment






Survival of lethally irradiated  
mice after treatment with INPROL




**FIG. 9**

Cell regeneration in BMLTC - L1210 cultures  
after combined AraC plus Inprol treatment




**FIG. 10A**

Cell regeneration in BMLTC - L1210 cultures  
after combined AraC plus Inprol treatment




**FIG. 10B**

30 days radioprotection by the bone marrow cells  
after preincubation with (B) or without (A) INPROL




**FIG. 11**

**Marrow repopulating ability of BDF1  
mice cells after incubation with SCP1**




**FIG. 12**

Pre-B progenitors number in Lymphoid Long Term Culture  
after preincubation with or without INPROL




**FIG. 13**

INPROL improves the repopulating ability  
(LTC-IC number) of leukemic peripheral blood cells



**FIG. 14**


FIG. 15A



Analysis: Channel A

Peak No.	Time	Type	Height(μY)	Area(μY-sec)	Area%
1	3.126	N1	691	7578	0.041
2	3.315	N2	1011	5150	0.027
3	49.618	N	8584	349227	1.893
4	51.298	N	1456	20274	0.109
5	52.673	N1	138069	2633395	14.278
6	53.148	N2	271587	14050458	76.181
	54.935	N3	33016	1332820	7.226
	67.595	N	3270	44507	0.241
TOTAL AREA				18443409	99.996





Analysis: Channel A

Peak No.	Time	Type	Height( $\mu$ Y)	Area( $\mu$ Y-sec)	Area%
1	4.383	N1	3945	95125	0.119
2	5.080	N2	28639	330889	0.413
3	5.216	N3	49084	531867	0.665
4	7.980	N1	399424	1110511	1.389
5	8.100	Err	1203320	2882013	3.605
6	8.241	N3	443249	1506159	1.884
7	8.386	N4	481563	2185702	2.734
8	8.533	N5	412886	1826165	2.284
9	8.701	N6	321500	842122	1.053
10	8.745	N7	404661	1610380	2.014
11	8.995	N8	435765	2489721	3.114
12	9.316	N9	517790	4801831	6.007

**FIG. 15B**

1 2 3



*FIG. 15C*

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
Val	Leu	Ser	Pro	Ala	Asp	Lys	Thr	Asn	Val	Lys	Ala	Ala	Trp	Gly	Lys	Val	Gly	Ala	His	
GTG	CTG	TCT	CCT	GCC	GAC	AAG	ACC	AAC	GTC	AAG	GCC	GCC	TGG	GGT	AAG	GTC	GGC	GGC	CAC	
21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	
Ala	Gly	Glu	Tyr	Gly	Ala	Glu	Ala	Leu	Glu	Arg	Met	Phe	Leu	Ser	Phe	Pro	Thr	Thr	Lys	
GCT	GGC	GAG	TAT	GGT	GCG	GAG	GCC	CTG	GAG	AGG	ATG	TTC	CTG	TCC	TTC	CCC	ACC	ACC	AAG	
41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	
Thr	Tyr	Phe	Pro	His	Phe	Asp	Leu	Ser	His	Gly	Ser	Ala	Gln	Val	Lys	Gly	His	Gly	Lys	
ACC	TAC	TTC	CCG	CAC	TTC	GAC	CTG	AGC	CAC	GCC	TCT	GCC	CAG	GTT	AAG	GGC	CAC	GGC	AAG	
61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	
Lys	Val	Ala	Asp	Ala	Leu	Thr	Asn	Ala	Val	Ala	His	Val	Asp	Asp	Met	Pro	Asn	Ala	Leu	
AAG	GTG	GCC	GAC	GCG	CTG	ACC	AAC	GCC	GTG	GCG	CAC	GTG	GAC	GAC	ATG	CCC	AAC	GCG	CTG	
81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	
Ser	Ala	Leu	Ser	Asp	Leu	His	Ala	His	Lys	Leu	Arg	Val	Asp	Pro	Val	Asn	Phe	Lys	Leu	
TCC	GCC	CTG	AGC	GAC	CTG	CAC	GCG	CAC	AAG	CTT	GCG	GTG	GAC	CCG	GTC	AAC	TTC	AAG	CTC	
101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	
Leu	Ser	His	Cys	Leu	Leu	Val	Thr	Leu	Ala	Ala	His	Leu	Pro	Ala	Glu	Phe	Thr	Pro	Ala	
CTA	AGC	CAC	TGC	CTG	CTG	GTG	ACC	CTG	GCC	GCC	CAC	CTC	CCC	GCC	GAG	TTC	ACC	CCT	GCG	
121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141
Val	His	Ala	Ser	Leu	Asp	Lys	Phe	Leu	Ala	Ser	Val	Ser	Thr	Val	Leu	Thr	Ser	Lys	Tyr	Arg
GTG	CAC	GCC	TCC	CTG	GAC	AAG	TTC	CTG	GCT	TCT	GTG	AGC	ACC	GTG	CTG	ACC	TCC	AAA	TAC	GCT


Fig. 16A



		10	20	30	40	50	
hHemA.pep	1	V-LSPADKIN	VRAAMGAVCA	HA-GEYCHER	LE-RMFLSEF	TKTYFPFH	50
hHemB.pep	1	VHLTPPEKSA	VPL-LGAT	-NVDEVGGR	LG-RULVWYF	WTQRFESFG	50
mHemA.pep	1	V-LSGEDKSN	IRAAAGHIGG	HG-AEYCHER	LE-RMFASER	TKTYFPFH	50
mHemB.pep	1	VHLIDAEKAA	VSCLEAGANS	D---EVGGER	L-GRLLWYF	WTQRFDSFG	50
pHemA.pep	1	V-LSAADKAN	VKAAGGATGG	QA-CAHCHER	LE-RMFLGER	TKTYFPFH	50
pHemB.pep	1	VHLSAEEKER	VLGLVGAENV	D---EVGGER	L-GRLLWYF	WTQRFESFG	50
		60	70	80	90	100	
hHemA.pep	51	DLSH-----G	SAQVGHGKKA	VADALTN---	AVAHVDDMEN	ALS--ALSDL	100
hHemB.pep	51	DLSITPDAVMG	NPKVKAHGKA	VLGA---FSD	GLAHLDNLKG	TFA--TLSEL	100
mHemA.pep	51	DVSH-----G	SAQVGHGKKA	VADALAS---	AAGHLDLPG	ALS--ALSDL	100
mHemB.pep	51	DLSSASAIMG	NAKVKAHGKA	V---ITAFND	GLNHLDNLKG	TFASL--SEL	100
pHemA.pep	51	NLSH-----G	SDQVKAHQKA	VADALTK---	AVGHLDLPG	ALS--ALSDL	100
pHemB.pep	51	DLSNADAVMG	NPKVKAHGKA	V---LQSFSD	GLKHLDNLKG	TFAKL--SEL	100
		110	120	130	140	150	
hHemA.pep	101	HAHKLRVDPV	NFKLLSHCLL	VTLAAHPAE	FTPAVHASLD	-KFLASVSTV	150
hHemB.pep	101	HCDKLHVDPE	NFRLLGNVIV	CVLAHFCKE	FTPEVQAAYQ	-KWAGVANA	150
mHemA.pep	101	HAHKLRVDPV	NFKLLSHCLL	VTLASHHPAD	FTPAVHASLD	-KFLASVSTV	150
mHemB.pep	101	HCDKLHVDPE	NFRLLGNMTV	IVLGHILGKD	FTPAQAQAF-	OKVWAGVATA	150
pHemA.pep	101	HAHKLRVDPV	NFKLLSHCLL	VTLAAHPDD	ENPSVHASLD	-KFLANVSTV	150
pHemB.pep	101	HCDQLHVDPE	NFRLLGNVIV	VVLARRLGHD	ENPDVQAQAF-	OKVWAGVANA	150
		160	170	180	190	200	
hHemA.pep	151	LTSKYR....	.....	.....	.....	.....	200
hHemB.pep	151	LAHKYH....	.....	.....	.....	.....	200
mHemA.pep	151	LTSKYR....	.....	.....	.....	.....	200
mHemB.pep	151	LAHKYH....	.....	.....	.....	.....	200
pHemA.pep	151	LTSKYR....	.....	.....	.....	.....	200
pHemB.pep	151	LAHKYH....	.....	.....	.....	.....	200

Fig. 16c


Fig 17 A



Analysis: Channel A

Peak No	Time	Type	Height(μV)	Area(μV-sec)	Area%
1	48.200	N	1677	20438	1.515
2	52.076	N1	7629	116393	8.631
3	52.510	N2	32010	381490	65.369
4	53.660	N3	10066	330153	24.485
Total Area				1348474	99.998

Fig. 17 B



Analysis: Channel A

Peak No.	Time	Type	Height(μV)	Area(μV-sec)	Area%
1	47.110	N1	1727	24840	0.204
2	47.723	N2	75067	1738939	14.321
3	49.153	N3	188795	6206410	51.114
4	52.250	N1	81476	3046748	25.092
5	53.113	N2	13195	202166	1.664
6	53.613	N3	19211	914954	7.535
	65.753	N	818	8066	0.066
Total Area				12142123	99.996




Fig. 18

Fig. 19 A




Fig. 19 B





# Comparison of Inprol and Hemoglobin Chains in FDCPmix Assay




Fig. 20